ASCOs growing roster of cutting-edge journals serves readers as the most credible, authoritative, peer-reviewed resources for significant clinical oncology research and research that informs the delivery of efficient, high-quality cancer care across the globe. Submit an Abstract ; Exhibitor Information ; Joint Sessions & Endorsements ; keyboard_arrow_left Back . EGRET: A first-in-human study of the novel antibody-drug conjugate (ADC) AZD9592 as monotherapy or combined with other anticancer agents in patients (pts) with advanced solid tumors. Abstract Submission Launches LATE SEPTEMBER 2022 Registration and Housing Websites Open OCTOBER 11, 2022 at 11:59 PM (ET) Abstract Submission Deadline NOVEMBER 2022 Abstract Notifications Sent to First Authors by Email DECEMBER 13, 2022 at 12:00 PM NOON (ET) TROPION-Lung04: Phase 1b, multicenter study of datopotamab deruxtecan (Dato-DXd) in combination with immunotherapy carboplatin in advanced/metastatic non-small cell lung cancer (mNSCLC). Download the ASCO GU Symposium Virtual Background to use when recording your presentation in Zoom. Interpolation was done to be used as the contour of the TDOM value in the survey area. 2318 Mill Road, Suite 800, Alexandria, VA 22314 571-483-1300 2023American Society of Clinical Oncology (ASCO). ASCOs growing roster of cutting-edge journals serves readers as the most credible, authoritative, peer-reviewed resources for significant clinical oncology research and research that informs the delivery of efficient, high-quality cancer care across the globe. Study area and the measurement locations. Multidisciplinary Thoracic Cancers Symposium, AACR/ASCO Methods in Clinical Cancer Research Workshop, Combined Hematology/Oncology and Hospice & Palliative Medicine Training, Quality Oncology Practice Initiative (QOPI), Patient-Centered Standards for Medically Integrated Dispensing, Standards for Safe Handling of Hazardous Drugs, Policies for Volunteers & Committee Members. This website provides access to information from Astellas sponsored clinical trials and the purpose is not to promote or advertise any Read about our latest progress around our Corporate Strategic Plan. The red star depicts the epicenter of the 16 January 2017 M5.2 earthquake. When the value of the consistency ratio is less than 0.1 (CR<0.1), it can be concluded that the level of consistency in the pair comparisons is quite rational (Saaty 1994). ASCO Genitourinary . A total of 15 abstracts, covering three approved medicines and one investigational therapy, will be presented underscoring the company's focus on pursuing targeted therapies for hard-to-treat cancers where few therapies exist, including prostate, urothelial, gastric/gastroesophageal junction (GEJ) and head & neck cancers, as well as acute myeloid leukemia (AML). All posters will receive a complimentary design review to check for image issues, table/chart legibility, etc. Get Involved. The location is selected on a surface with a flat contour; the geophone is installed in an inline configuration with a distance of 2m. Measurements were made using the fixed spread method (the location of the geophone sensor does not move). 2015). Abstract Number: 6017. This medium soil (SD) and soft soil (SE) dominate almost all Medan City areas, it can be seen in Fig. San Francisco, CA. Treatment for early-stage, low-risk cervical cancers may be safely de-escalated with the use of SH, which may help improve quality of life for patients. Additionally, those in the SH group experienced fewer intraoperative urological surgical complications and fewer immediate and long-term bladder problems. Simple hysterectomy with pelvic node dissection is a safe treatment option for people with early-stage, low-risk cervical cancer and may help improve quality of life, according to results from a large, international phase III clinical trial. AstraZeneca is collaborating with Daiichi Sankyo Company Limited to develop and commercialise Enhertu and datopotamab deruxtecan; with MSD (Merck & Co., Inc. in the US and Canada) to develop and commercialise Lynparza. We will showcase significant steps toward that goal with overall survival data from ADAURA that reinforce Tagrisso as the backbone therapy in EGFR-mutated lung cancer., Susan Galbraith, Executive Vice President, Oncology R&D, AstraZeneca, said: We are extending the benefits of our practice-changing cancer medicines, including Tagrisso, Imfinzi and Lynparza, while also investing in new scientific platforms such as T-cell engagers and cell therapy to attack cancer from multiple angles and advance the next wave of options for patients. In this study, we presented the result of the geophysical survey first (MASW, SPAC, and HVSR results), followed by the discussions on the Medan City environment, geotechnical and environmental analysis, and finally discussions on the potential environmental damage in Medan City due to earthquake shaking. Rainfall in the Medan city area is generally classified as medium rainfall (class 2) with an average rainfall range of 190220mm (Fig. MASW measurements use 24 geophone sensors with a frequency of 4.5Hz and a 10kg hammer. DOI: 10.1200/JCO.2023.41.16_suppl.TPS4607 Journal of Clinical Oncology - published online before print May 31, 2023 A phase II study of olaparib (AZD2281) in patients (Pts) with metastatic/advanced urothelial carcinoma and other genitourinary (GU) tumors with DNA-repair defects. June 5, 5:04 pm CDT. Medan is the capital city of North Sumatra Province, Indonesia, which is surrounded by active faults (Natawidjaja 2018; Sieh and Natawidjaja 2000). Numerical processing purposes to obtain the average rainfall and spatial processing for rainfall data for all sub-districts in the city of Medan through an interpolation approach. In addition to the figures, the results are also presented as Tables in the supplementary material. DK: supervision. If necessary you may include the proprietary drug name in parenthesis directly after the generic name on first use in the body of the abstract. ", Astellas Presentations at 2023 ASCO Annual Meeting, A first-in-human trial of intravesical enfortumab vedotin (EV), an antibody-drug conjugate (ADC), in patients with non-muscle invasive bladder cancer (NMIBC): Interim results of a phase 1 study (EV-104), Poster Session: Genitourinary Cancer Kidney and Bladder, Study EV-103 dose escalation/cohort A: Long-term outcome of enfortumab vedotin + pembrolizumab in first-line (1L) cisplatin-ineligible locally advanced or metastatic urothelial carcinoma (la/mUC) with nearly 4 years of follow-up, Oral Abstract Session: Genitourinary Cancer Kidney and Bladder, Enfortumab vedotin in the previously treated advanced head and neck cancer (HNC) cohort of EV-202, EV-203: Phase 2 trial of enfortumab vedotin in patients with previously treated advanced urothelial carcinoma in China, Study EV-103: Neoadjuvant treatment with enfortumab vedotin monotherapy in cisplatin-ineligible patients (pts) with muscle invasive bladder cancer (MIBC): Updated results for Cohort H, Enfortumab vedotin (EV) with or without pembrolizumab (P) in patients (pts) who are cisplatin-ineligible with previously untreated locally advanced or metastatic urothelial cancer (la/mUC): Additional 3-month follow-up on cohort K data, Real-world use, dose intensity, and adherence to an antibody-drug conjugate (ADC) in metastatic urothelial cancer (mUC), KEYNOTE-905/EV-303: A phase 3 study to evaluate the efficacy and safety of perioperative pembrolizumab or pembrolizumab plus enfortumab vedotin (EV) for muscle-invasive bladder cancer (MIBC), Longitudinal transcriptome profiling of localized hormone-sensitive tumors in treatment-nave ENACT patients with prostate cancer with and without enzalutamide (ENZA), Poster Session: Genitourinary Cancer Prostate, Testicular, and Penile, Outcomes of patients (pts) with de novo metastatic hormone-sensitive prostate cancer (mHSPC) who progressed to metastatic castration-resistant prostate cancer (mCRPC): a post-hoc analysis of the TRUMPET registry, Real-world baseline characteristics and first-line (1L) treatment (Tx) in patients (pts) with de novo metastatic castration-sensitive prostate cancer (mCSPC) by disease volume, Zolbetuximab + CAPOX in 1L claudin-18.2+ (CLDN18.2+)/HER2 locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: Primary phase 3 results from GLOW (Rapid abstract update presentation following March 22 Plenary Series session), Session: ASCO Plenary Series: Rapid Abstract Updates, Phase 2 trial of zolbetuximab in combination with mFOLFOX6 and nivolumab in patients with advanced or metastatic claudin 18.2-positive, HER2-negative gastric or gastroesophageal junction adenocarcinomas, Poster Session: Gastrointestinal Cancer Gastroesophageal, Pancreatic, and Hepatobiliary, Global prevalence of CLDN18.2 positivity in tumor samples from patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma: Biomarker analysis of two zolbetuximab phase 3 studies (SPOTLIGHT and GLOW), Work Absenteeism and Disability Days after Diagnosis among Patients with AML and Caregivers. No more worries about how to travel with your poster to the meeting. Data at meeting illustrate company's progress in addressing unmet needs in a broad range of hard-to-treat solid tumors and hematologic malignancies. Speaking of Urology: ASCO GU 2023 Highlights - Apple Podcasts 2b). Clinical activity of camizestrant, a next-generation SERD, versus fulvestrant in patients with a detectable ESR1 mutation: Exploratory analysis of the SERENA-2 Phase 2 trial. TROPION-Lung02 is the first trial to show results for an antibody drug conjugate (ADC) plus an immune checkpoint inhibitor combination with or without chemotherapy in this setting. Data will also be shared from a matching-adjusted indirect comparison (MAIC) of the efficacy and safety of Calquence (acalabrutinib) versus zanubrutinib in relapsed or refractory chronic lymphocytic leukemia, based on data from the ASCEND and ALPINE Phase III trials. During a SH, only the uterus and cervix are removed. Potential to transform outcomes across tumours by attacking cancer from multiple angles Abstract Policies, Embargoes & Exceptions | ASCO Annual Meeting Microzonation becomes important for big cities like Medan as population agglomeration increases in urban areas resulting in rapid and unplanned construction (Molnar et al. In this paper, all the data are included in the set of Additional file 1: Tables S1S17. Oral Abstract Session Lung CancerNon-Small Cell Metastatic. The results of measurements using the SPAC method show that the bedrock values varied with the dominant bedrock at 250450m depth (Fig. We thank the editorandreviewers for their constructive comments and suggestions to improve the quality of this paper. ASCO Genitourinary Cancers Symposium . 3b). "The research presented at ASCO reflects our intense focus on how we are continuing to grow the breadth and utility of our oncology portfolio and pipeline for the oncology community and patients with cancer, particularly those with advanced disease," said Ahsan Arozullah, MD, MPH, Senior Vice President, Head of Oncology Development, Astellas. Another oral presentation will feature a pooled benefit-risk analysis from the DESTINY-Breast01, 02 and 03 trials of Enhertu in patients with breast cancer aged 65 and older compared to those younger than 65. The Zoning Map of Potential Environmental Damage in Medan City was obtained from a combination of population density parameters, geotechnical parameters, and environmental parameters with the weight of each parameter, namely 28% Population Density parameter, 28% Soil Class parameter (MASW), 16% Seismic Vulnerability (KG), 9% Dominant Period (TDOM), 9% Land Cover, 5% Slope, and 5% Weather Conditions (Rainfall Class). The rate of positive surgical margins was low in both groups (2.6% overall; 2.1% with SH vs. 2.9% with RH). The early registration deadline is January 11, 2023. . The classification of soil slope class division is divided into 5 (five) classes, i.e., flat (08%), gentle (815%), slightly steep (1525%), steep (2545%) and very steep (>45%). During the period, several earthquakes on land were felt in the area, including the Deli Serdang Earthquake (M 5.2) on January 16, 2017, which was felt up to the III-IV on Modified Mercalli Intensity (MMI) scale. Cookies policy. Data processing is further divided into two, namely spatial processing and numerical processing. High complete response rate with TNB-486 in relapsed/refractory follicular lymphoma: Interim results an ongoing Phase 1 study. Color represents the class of geotechnical parameters from low to very high. Class division on environmental parameters was presented in Additional file 1: Tables S11S13 (according to regulation Permen PU No. Identification of a previously unidentified endemic region for - PubMed Poster Presenter Guidelines | Oncology Meetings Front Built Environ 3:30, Fathani TF, Wilopo W (2017) Seismic microzonation studies considering local site effects for Yogyakarta City, Indonesia. So, the results of the calculations on the normalized pairwise comparison matrix can be used as weights in making a compilation map of geophysical survey data and environmental data as well as population data. The person submitting the abstract is not required to be an author on the abstract and will be able to select the first/presenting author on the designated step. J Phys Theor Appl 1(2):8996, Irsyam M, Hutabarat D, Asrurifak M, Imran I, Widiyantoro S, Hendriyawan D, Sadisun I, Hutapea B, Firmanti A, Ridwan M, Iai S (2015) Development of seismic risk microzonation maps of Jakarta city. Any preliminary data including toxicity, response rate, pharmacokinetics, or correlative analyses. Seismic vulnerability analysis and local site effects can also be carried out on a smaller scale taking into account regional seismicity, geology, socioeconomic, population, and local site conditions (Hidayat et al. The final deadline is February 7, 2023, at 1:00 PM CST (rush charges apply). Color represents rainfall in mm. 2318 Mill Road, Suite 800, Alexandria, VA 22314 571-483-1300 2023 American Society of Clinical Oncology (ASCO). Overall, 21 pelvic recurrences were identified after a median follow-up of 4.5 years (11 in the SH group vs. 10 in the RH group). Because RH is a more complex surgery, it requires more extensive surgical training and is potentially associated with more acute and long-term side effects, such as bleeding, bladder and ureteral injury, and bladder and bowel dysfunction, as well as potential impacts on quality of life and sexual health. June 5, 12:54 pm CDT. Color represents the seismic vulnerability index. Your US state privacy rights, ASCO Daily News is the official conference reporter for ASCO meetings and symposia, providing high-quality, unbiased research summaries and oncology news to members and oncology health care providers. The website you are about to visit is not owned or controlled by Astellas. The result is also verified by empirical information from the damage due to the recent moderate-magnitude earthquake on 16 January 2017 (Fig. MD Fellowship | Genentech Secondary endpoints included extrapelvic relapse-free survival, relapse-free survival, overall survival, and quality of life. Based on the Compilation of Environmental Parameters of the Medan City Map, the areas with the highest risk parameter values are in the central to the southern region of Medan City, and the lowest areas are in the northern region (Fig. Astellas Highlights Continued Delivery of Strong Cancer Portfolio and ASCO Daily News is the official conference reporter for ASCO meetings and symposia, providing high-quality, unbiased research summaries and oncology news tomembers and oncology health care providers. This trial was initiated based on positive data for Enhertu in the DESTINY-CRC01 Phase II trial. Based on the results of the Compilation of Environmental Parameters for the City of Medan, it was found that the area that has the potential to have a significant impact on landslides is the downtown area of Medan because the slope is quite steep (1545%) and land cover in the form of dense settlements are in the area. Urban areas are more dangerous and high risk even for medium earthquakes (Celikbilek and Sapmaz 2016). Additionally, an oral presentation of primary results from the DESTINY-CRC02 Phase II trial will be presented, demonstrating the safety and efficacy of Enhertu in patients with HER2-positive advanced colorectal cancer with progression following standard-of-care treatment. 2014). Disaster Sci Eng 2(2):5966, Daniell JE, Schaefer AM, Wenzel F (2017) Losses associated with secondary effects in earthquakes. The results of calculations using a pairwise comparison matrix are presented in Additional file 1: Table S4. Posters left in the red Unchecked Poster Reclaim Bin will be discarded at the end of the Symposium. Date and time. 22. calendar_today Dates expand_less . By assembling vast amounts of usable, searchable, real-world data, CancerLinQ seeks to improve the quality and value of cancer care. Poster presenters may submit electronic audio/video recordings to accompany their online poster, offering a broader opportunity to share details on your research, All accepted ASCO abstracts are published on ASCO.org and available as an online supplement to the. To submit an abstract, you will need to log in with an ASCO.org account. Then the second level consists of 7 (seven) criteria, namely Population, Soil Class, KG, TDOM, Land Cover, Slope, and Weather. NeoCOAST-2: A Phase 2 study of neoadjuvant durvalumab plus novel immunotherapies (IO) and chemotherapy (CT) or MEDI5752 (volrustomig) plus CT, followed by surgery and adjuvant durvalumab plus novel IO or volrustomig alone in patients with resectable non-small-cell lung cancer (NSCLC). b Bottom left: incorporation of geotechnical dan environmental parameters. Such factors include, but are not limited to: (i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of Astellas to market existing and new products effectively, (v) the inability of Astellas to continue to effectively research and develop products accepted by customers in highly competitive markets, and (vi) infringements of Astellas' intellectual property rights by third parties. Researchers plan to further investigate the quality of life and sexual health data, conduct a cost-effectiveness and cost utility analysis of RH vs. SH, and identify risk factors associated with recurrences in future studies. The site uses cookies to provide you with a more responsive and personalized service and to analyze site traffic. We are promoting the Focus Area Approach that is designed to identify opportunities for the continuous creation of new drugs to address diseases with high unmet medical needs by focusing on Biology and Modality. Practice & Patients. /news-initiatives/cancer-progress-timeline, /get-involved/volunteering-committees/volunteer-asco, Multidisciplinary Head and Neck Symposium, Multidisciplinary Thoracic Cancers Symposium, AACR/ASCO Methods in Clinical Cancer Research Workshop, Combined Hematology/Oncology and Hospice & Palliative Medicine Training, Pharmaceutical and Device Pipeline Directory, Quality Oncology Practice Initiative (QOPI), Patient-Centered Standards for Medically Integrated Dispensing, Standards for Safe Handling of Hazardous Drugs, ASCO Statement on the Earthquakes in Turkey & Syria, Information for Patients With Cancer & Physicians in Ukraine & Neighboring Countries, Policies for Volunteers & Committee Members, Osimertinib After Surgery Significantly Improves Survival in Patients With Resected EGFR-Mutated Non-Small Cell Lung Cancer, Vorasidenib Delays Disease Progression or Death in Grade 2 Glioma With IDH Mutation, Nivolumab Reduces Risk of Disease Progression or Death in Untreated Hodgkin Lymphoma Compared to Brentuximab, Antibody-Microtubule Inhibitor Conjugate Improves Survival in Women With Recurrent Ovarian Cancer, Radiation Can Be Safely Omitted in Select Patients With Locally Advanced Rectal Cancer, 700 people ages 24-80 with low-risk, early-stage disease were randomized to receive pelvic node dissection and RH or SH, 50% of the hysterectomies were done laparoscopically (56% SH vs. 44% RH); 25% robotically (24% SH vs. 25% RH); and 23% abdominally (17% SH vs. 29% RH).